Bicycle Therapeutics PLC (BCYC)
21.38
-0.80
(-3.63%)
USD |
NASDAQ |
May 17, 16:00
21.38
0.00 (0.00%)
Pre-Market: 20:00
Bicycle Therapeutics Research and Development Expense (Quarterly): 34.86M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 34.86M |
| December 31, 2023 | 44.70M |
| September 30, 2023 | 39.87M |
| June 30, 2023 | 39.72M |
| March 31, 2023 | 32.21M |
| December 31, 2022 | 24.72M |
| September 30, 2022 | 22.75M |
| June 30, 2022 | 19.85M |
| March 31, 2022 | 14.28M |
| December 31, 2021 | 12.96M |
| September 30, 2021 | 10.51M |
| June 30, 2021 | 11.72M |
| March 31, 2021 | 9.693M |
| Date | Value |
|---|---|
| December 31, 2020 | 10.06M |
| September 30, 2020 | 7.363M |
| June 30, 2020 | 7.958M |
| March 31, 2020 | 7.774M |
| December 31, 2019 | 6.649M |
| September 30, 2019 | 6.078M |
| June 30, 2019 | 6.537M |
| March 31, 2019 | 6.276M |
| December 31, 2018 | 6.493M |
| September 30, 2018 | 5.642M |
| June 30, 2018 | 4.917M |
| March 31, 2018 | 3.709M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.078M
Minimum
Sep 2019
44.70M
Maximum
Dec 2023
18.51M
Average
12.34M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 8.519M |
| TC BioPharm (Holdings) PLC | -- |
| Adaptimmune Therapeutics PLC | 35.21M |
| Verona Pharma PLC | 6.764M |